A phase II/III trial of GC-1102

Trial Profile

A phase II/III trial of GC-1102

Phase of Trial: Phase II/III

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs GC 1102 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors GC Pharma
  • Most Recent Events

    • 19 Jan 2018 New trial record
    • 17 Jan 2018 According to a Green Cross Pharma media release, the company expects to initiate patient enrollment in early 2018 and expects to complete the trial in 5 years.
    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top